Fingolimod for PPMS trial

The INFORMS trial has found that fingolimod (Gilenya) was no better than placebo at treating people with primary progressive MS. Novartis press release Reuters Primary progressive MS: an introduction
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news